SL Science Holding SLBT stock fell to $3.95 during today’s trading session as investors assessed widening losses, declining revenue and an early-stage cell-therapy pipeline.

Key Highlights

  • Shares declined 12.61% to approximately $3.95 after closing the previous session at $4.52.
  • Two-session losses reached nearly 32% following the earlier 21.93% decline.
  • Full-year revenue fell 35% to $2.20 million, while the net loss widened to $3.82 million.
  • A $7.8 million PIPE provides new capital, but the principal cell-therapy programmes remain preclinical.

SLBT Extends Its Decline After a Volatile Nasdaq Debut

SL Science Holding Limited (NASDAQ:SLBT) traded near $3.95 during today’s session, falling $0.57 from its previous close of $4.52. The shares opened at $4.09 and moved between $3.84 and $4.24 before remaining close to the lower end of the range.

The decline followed a 21.93% fall in the preceding session, when the stock closed at $4.52 on volume of approximately 349,000 shares. Across the two sessions, SLBT has lost nearly 32% from its estimated level before the initial selloff.

The shares are now trading close to the lower portion of their displayed $3.00 to $14.50 range. At $3.95, the stock is roughly 73% below the upper end of that interval.

No newer operating announcement was identified after the company’s June 18 financial results. The latest decline therefore appears to extend the price adjustment that followed SL Science’s recent Nasdaq listing and its first detailed financial update as a public company.

The short trading history is important. SL Science completed its business combination with Horizon Space Acquisition II on June 12, and its ordinary shares began trading under the SLBT ticker on June 15. The transaction carried an implied equity valuation of approximately $5.57 billion and closed alongside a $7.8 million private investment.

Recent Financial Results Add Pressure to the Valuation

SL Science reported full-year 2025 revenue of approximately $2.20 million, down 35% from $3.36 million in 2024. The company attributed the decline to a planned shift in its Taiwan operation from direct retail sales of exosome products to a wholesale distribution model.

The change affected both sales volume and profitability. Gross profit fell 60% to approximately $775,000, while cost of revenue declined by only 1% to $1.42 million. The greater proportion of lower-margin wholesale transactions meant that revenue contracted much faster than product costs.

Operating expenses increased 47% to approximately $4.61 million. General and administrative spending more than doubled to $2.54 million, while research and development expenditure remained near $2.07 million.

The combination of lower revenue and higher expenses widened the annual net loss to approximately $3.82 million from $1.19 million. The operating loss increased to $3.84 million from about $1.20 million.

Those figures may be contributing to the current reassessment of SLBT stock. The company has a commercial exosome operation, but its central investment case increasingly depends on therapies that have not yet generated revenue.

Cell-Therapy Programmes Remain at an Early Stage

SL Science is developing CD-19 Armed-T and Gamma Delta T cell platforms for cancer treatment. Its research includes potential applications in blood cancers and solid tumours, including pancreatic and brain cancers.

The company describes these immune-cell technologies as preclinical. Its Gamma Delta T strategy is intended to produce scalable, ready-to-use treatments rather than therapies manufactured separately for each patient.

However, neither the CD-19 Armed-T segment nor the Gamma Delta T cell-therapy segment generated revenue during 2025. All reported revenue came from exosome products.

For the CD-19 programme, the company is conducting further nonclinical validation and manufacturing work after receiving initial regulatory feedback. Management is targeting a pre-investigational meeting and formal application during the first quarter of 2027.

The unmodified Gamma Delta T programme remains on a longer schedule. The company expects toxicology work to begin after manufacturing reagents are delivered in the first quarter of 2027, supporting a targeted regulatory filing in the third quarter of that year. These dates remain company objectives rather than completed milestones.

The timeline means the stock’s valuation may remain sensitive to manufacturing updates, preclinical evidence and regulatory progress rather than near-term product sales.

PIPE Financing Improves Funding but Cash Use Remains Relevant

SL Science ended December 2025 with approximately $1.26 million of restricted and unrestricted cash, down from $4.14 million one year earlier.

Operating activities consumed about $1.91 million during the year. The company also incurred roughly $880,000 of deferred offering costs connected with the public listing process.

The $7.8 million PIPE completed with the business combination therefore represents an important addition to the funding position. The proceeds are intended to support research, clinical preparation and the broader growth strategy.

However, SL Science has not yet published a post-closing balance sheet showing the final amount of available cash after transaction fees and other merger-related costs. Its future capital requirements will depend on the speed of preclinical work, manufacturing scale-up and regulatory preparation.

Early-stage biotechnology development can require repeated funding before a therapy reaches commercialisation. Additional equity financing could extend the development runway, but it may also increase the outstanding share count.

The Post-Merger Structure Adds Trading Risk

The shares have been publicly traded under the SLBT symbol for only a brief period. Newly completed business combinations can experience large price movements while market participants assess the final ownership structure, public float and valuation.

The merger announcement cited an implied equity valuation of approximately $5.57 billion. That transaction figure was based on the agreed combination terms and should not be interpreted as a current valuation derived directly from today’s share price.

SLBT’s wide recent range suggests that price discovery remains unsettled. The stock has moved sharply despite the absence of daily operating announcements, indicating that liquidity and positioning may be influencing short-term movements alongside the company’s financial disclosures.

The latest results provide investors with clearer operating information, but they also expose the tension in the investment case. SL Science has a newly funded development platform and access to US capital markets, while revenue has declined, losses have widened and its principal therapeutic programmes remain preclinical.

What Could Shape SLBT Stock Next

The next important developments may include manufacturing progress, completion of additional nonclinical work and confirmation of regulatory meeting schedules.

Investors may also look for a post-combination balance sheet showing cash resources, transaction expenses and the number of shares outstanding. Those details would provide a clearer basis for evaluating funding capacity and market valuation.

Future exosome-product revenue will indicate whether the wholesale transition can produce a more stable commercial base. Research expenditure and administrative costs will show how quickly the company is using its newly raised capital.

For today’s trading session, the confirmed development is a 12.61% decline to approximately $3.95. The stock has now fallen nearly 32% across two sessions as the market weighs an early-stage oncology pipeline against lower revenue, wider losses and continuing funding requirements.